These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Guidelines on psychotropic drugs for the EC. Clinical investigation of medicinal products in the treatment of generalized anxiety disorder, panic disorder and obsessive-compulsive disorder. Eur Neuropsychopharmacol; 1995 Jun; 5(2):151-5. PubMed ID: 7549458 [No Abstract] [Full Text] [Related]
3. Pharmacotherapy of anxious disorders. Bourin M; Lambert O Hum Psychopharmacol; 2002 Dec; 17(8):383-400. PubMed ID: 12457374 [TBL] [Abstract][Full Text] [Related]
4. Let's talk facts about anxiety disorders. American Psychiatric Association J Okla State Med Assoc; 2008 Dec; 101(12):347-50. PubMed ID: 19177997 [No Abstract] [Full Text] [Related]
5. Recent advances in the understanding and treatment of anxiety disorders. Shearer SL Prim Care; 2007 Sep; 34(3):475-504, v-vi. PubMed ID: 17868756 [TBL] [Abstract][Full Text] [Related]
6. Are placebo-controlled trials still important for obsessive compulsive disorder? Fineberg NA; Hawley CJ; Gale TM Prog Neuropsychopharmacol Biol Psychiatry; 2006 May; 30(3):413-22. PubMed ID: 16413647 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of neurosis and placebo effect]. Temkov I; Dimitrov C Schweiz Arch Neurol Neurochir Psychiatr; 1973; 113(2):357-68. PubMed ID: 4590956 [No Abstract] [Full Text] [Related]
9. Management of comorbid anxiety and depression. Zajecka JM; Ross JS J Clin Psychiatry; 1995; 56 Suppl 2():10-3. PubMed ID: 7844101 [TBL] [Abstract][Full Text] [Related]
10. The effect of anxiety disorder comorbidity on treatment resistant bipolar disorders. Lee JH; Dunner DL Depress Anxiety; 2008; 25(2):91-7. PubMed ID: 17311265 [TBL] [Abstract][Full Text] [Related]
11. Pharmacotherapy of comorbid mood, anxiety, and substance use disorders. Brady KT; Verduin ML Subst Use Misuse; 2005; 40(13-14):2021-41, 2043-8. PubMed ID: 16282091 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of major psychotropic medications: critical role for psychiatric nursing. Fox J ANA Publ; 1994 May; (PMH-13 10 M):56-8. PubMed ID: 8048766 [No Abstract] [Full Text] [Related]
13. The assessment and treatment of refractory anxiety. Hollander E; Cohen LJ J Clin Psychiatry; 1994 Feb; 55 Suppl():27-31. PubMed ID: 7915712 [TBL] [Abstract][Full Text] [Related]
17. Obsessive-compulsive spectrum conditions in obsessive-compulsive disorder and other anxiety disorders. Richter MA; Summerfeldt LJ; Antony MM; Swinson RP Depress Anxiety; 2003; 18(3):118-27. PubMed ID: 14625876 [TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical characteristics, co-morbidity and pharmacotherapy in adolescent schizophrenia patients with and without obsessive-compulsive disorder. Poyurovsky M; Faragian S; Shabeta A; Kosov A Psychiatry Res; 2008 May; 159(1-2):133-9. PubMed ID: 18406469 [TBL] [Abstract][Full Text] [Related]
19. D-cycloserine does not enhance exposure-response prevention therapy in obsessive-compulsive disorder. Storch EA; Merlo LJ; Bengtson M; Murphy TK; Lewis MH; Yang MC; Jacob ML; Larson M; Hirsh A; Fernandez M; Geffken GR; Goodman WK Int Clin Psychopharmacol; 2007 Jul; 22(4):230-7. PubMed ID: 17519647 [TBL] [Abstract][Full Text] [Related]